Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
Frontiers in Immunology
|
October 10, 2022
Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities
Quentin Haas, Nikita Markov, Lukas Muerner, et al.
Molecular Cancer Therapeutics
|
May 5, 2017
The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34<sup>+</sup> Stem/Progenitor Cells
Maximilien Murone, Ramin Radpour, Antoine Attinger, et al.
Cell Death and Differentiation
|
December 18, 2019
ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics
He Liu, Zhaoyue He, Nina Germič, et al.
Leukemia
|
September 26, 2022
Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance
Elias D Bührer, Michael A Amrein, Stefan Forster, et al.
Nature Communications
|
April 4, 2020
TNIK signaling imprints CD8<sup>+</sup> T cell memory formation early after priming
Carla A Jaeger-Ruckstuhl, Magdalena Hinterbrandner, Sabine Höpner, et al.
Frontiers in Immunology
|
June 4, 2019
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine
Mona O Mohsen, Monique Vogel, Carsten Riether, et al.
Blood
|
January 27, 2026
High-Dimensional Spatiotemporal Single-Cell Atlas and 3D imaging of Bone Marrow Microenvironment during CML Progression
Lanzhu Li, Isabelle Rottmann, Borhan R Saeed, et al.
Haematologica
|
February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
Thomas Pabst, Norbert Vey, Lionel Adès, et al.
Oncogene
|
September 2, 2018
mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer
Shun-Qing Liang, Elias D Bührer, Sabina Berezowska, et al.
The Journal of Clinical Investigation
|
May 27, 2015
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
Lukas F Mager, Carsten Riether, Christian M Schürch, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
Frontiers in Immunology
|
October 10, 2022
Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities
Quentin Haas, Nikita Markov, Lukas Muerner, et al.
Molecular Cancer Therapeutics
|
May 5, 2017
The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34<sup>+</sup> Stem/Progenitor Cells
Maximilien Murone, Ramin Radpour, Antoine Attinger, et al.
Cell Death and Differentiation
|
December 18, 2019
ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics
He Liu, Zhaoyue He, Nina Germič, et al.
Leukemia
|
September 26, 2022
Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance
Elias D Bührer, Michael A Amrein, Stefan Forster, et al.
Nature Communications
|
April 4, 2020
TNIK signaling imprints CD8<sup>+</sup> T cell memory formation early after priming
Carla A Jaeger-Ruckstuhl, Magdalena Hinterbrandner, Sabine Höpner, et al.
Frontiers in Immunology
|
June 4, 2019
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine
Mona O Mohsen, Monique Vogel, Carsten Riether, et al.
Blood
|
January 27, 2026
High-Dimensional Spatiotemporal Single-Cell Atlas and 3D imaging of Bone Marrow Microenvironment during CML Progression
Lanzhu Li, Isabelle Rottmann, Borhan R Saeed, et al.
Haematologica
|
February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
Thomas Pabst, Norbert Vey, Lionel Adès, et al.
Oncogene
|
September 2, 2018
mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer
Shun-Qing Liang, Elias D Bührer, Sabina Berezowska, et al.
The Journal of Clinical Investigation
|
May 27, 2015
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
Lukas F Mager, Carsten Riether, Christian M Schürch, et al.
Page
of 8